<DOC>
	<DOCNO>NCT02104869</DOCNO>
	<brief_summary>This open label , parallel , randomize clinical trial evaluate immunogenicity safety trivalent influenza vaccine ( inactivate fragment ) produce Instituto Butantan among adult kidney transplant recipient , administer three vaccination regimen : ) recommend dose ; ii ) single double dose ; iii ) two dos administer 21 day interval . The randomization ratio among three group kidney transplant recipient 1:1 , 60 participant include group . After vaccination participant follow 26 week . In addition , 15 healthy adult include control group , receive recommend dose . The study hypothesis different vaccination regimen improve immune response kidney transplant recipient vaccination trivalent influenza vaccine ( inactivate fragment ) .</brief_summary>
	<brief_title>Clinical Trial Evaluation Three Regimens Influenza Vaccination Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Kidney Transplant Recipients Kidney transplant 30 day ; 18 59 year age ; Functioning graft ( patient without indication dialysis time , regardless glomerular filtration rate ) ; Ability understand engage procedure require participation study ; Willingness participate documented signature ICF . Double transplant ( organ besides kidney ) ; Graft loss ; HIV infection malignancy ; Known systemic hypersensitivity component vaccine , thimerosal , neomycin , formaldehyde , Triton X100 ( octoxynol 9 ) , egg chicken protein , drug substance contain component vaccine previous administration product ; Any acute condition and/or fever within 7 day prior vaccination axillary temperature great 37,8°C day vaccination ; Have receive live virus vaccine within 28 day kill virus vaccine last 14 day prior vaccination , schedule immunization first 21 day inclusion study ; Behavioral , cognitive psychiatric disease opinion principal investigator representative physician , affect participant ability understand cooperate study protocol requirement ; Use investigational product within 42 day prior inclusion study ( visit V0 ) schedule receive inclusion study ( visit V0 ) ; Inclusion another clinical trial six month prior vaccination ; Denies permission biological material storage future research define ICF ; Any condition , investigator 's opinion representative , might put risk safety/rights potential participant could hamper his/her compliance protocol . Healthy Adults Healthy adult sex 18 59 year age ; Be available participate entire study period ; Demonstrate intent participate study , document sign IC . Evidence active neurological , cardiac , pulmonary , hepatic renal disease clinical history , physical examination and/or laboratory result ; Compromised immune system diseases include : diabetes mellitus , cancer ( except basal cell carcinoma ) autoimmune disease ; Behavioral , cognitive psychiatric disease opinion principal investigator representative physician , affect participant ability understand cooperate study protocol requirement ; Abusive usage alcohol drug past 12 month cause medical , professional family problem , indicate clinical history ; Known systemic hypersensitivity component vaccine , thimerosal , neomycin , formaldehyde , Triton X100 ( octoxynol 9 ) , egg chicken protein , drug substance contain component vaccine previous administration product ; Diagnosis asthma history hospitalization last six month due illness ; Any acute illness and/or fever 7 day prior study inclusion axillary temperature great 37.8 ° C day vaccination ( visit V0 ) ; Use corticosteroid ( except topical nasal ) immunosuppressive drug within 42 day study initiation/baseline . It consider immunosuppressive dose corticosteroid equivalent dose ≥10 mg prednisone per day 14 day ; Use anticoagulant medication ; Have receive live virus vaccine within 28 day kill virus vaccine last 14 day prior vaccination , schedule immunization first 42 day receive investigational product ; History asplenia ; Have receive blood product past six month , include transfusion immunoglobulin , schedule administration blood product immunoglobulin first 42 day vaccination ; Use investigational product within 42 day receive study vaccination ; Has participate another clinical trial six month prior vaccination ; Denies permission biological material storage future research define ICF ; Any condition might put risk safety/rights potential participant hurdle his/her compliance protocol investigator 's opinion representative physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Influenza vaccine</keyword>
</DOC>